Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

Richard A. Larson,Andreas Hochhaus,Timothy P. Hughes,Richard E. Clark,Gabriel Etienne,D. W. Kim,Ian W. Flinn,Mineo Kurokawa,Beatriz Moiraghi,Richard Yu,Rick E. Blakesley,Neil Gallagher,G. Saglio,Hagop M. Kantarjian

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

2012

Richard A. Larson
Andreas Hochhaus
Timothy P. Hughes
Richard E. Clark
Gabriel Etienne
D. W. Kim
Ian W. Flinn
Mineo Kurokawa
Beatriz Moiraghi
Richard Yu
Rick E. Blakesley
Neil Gallagher
G. Saglio
Hagop M. Kantarjian

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

Keywords:

Cancer research
Ponatinib
Lymphoma
Nilotinib
Myeloid leukemia
Hematology
Philadelphia Chromosome Positive
Leukemia
Oncology
Imatinib
Immunology
Biology
Internal medicine
Myelogenous
imatinib mesylate
Bosutinib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

371

Citations